Extract
Elexacaftor/tezacaftor/ivacaftor (ETI) is a modulator therapy recently approved for patients with cystic fibrosis (CF) with at least one F508del mutation. The resulting impact on the health of CF patients has been tremendous, improving many clinical aspects (e.g. sweat chloride, lung function and reduction in pulmonary exacerbation) of this complex disease, and enhancing patients’ quality of life [1].
Abstract
Elexacaftor/tezacaftor/ivacaftor treatment improves the antimicrobial function of monocytes/macrophages http://bit.ly/3ZvIsxZ
Footnotes
Published in volume 61, issue 4 of the European Respiratory Journal on 1 April 2023; republished 10 April 2023 to address typographical errors in the medication names elexacaftor and tezacaftor.
Conflict of interest: The author declares no competing interests.
- Received February 6, 2023.
- Accepted February 25, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org